Clinical Care

Most of the largest mortality levers on this site are behavioral: sleep, exercise, diet, smoking cessation, social connection. But a small set of clinical interventions delivers effect sizes that lifestyle alone cannot match in the populations where they matter — testosterone replacement in deficient men with cardiometabolic disease, menopausal hormone therapy initiated within the critical window after menopause, GLP-1 receptor agonists in obesity, statins for elevated apoB, hearing aids for midlife hearing loss. This pillar collects the evidence on those interventions, plus the screening cadences that decide who actually benefits. The voice is the same as everywhere else on the site: what the evidence shows, what's overhyped, and where the limits of current data sit.

What the evidence actually supports

Strong:

• Wilder's Law of Initial Value holds across this pillar: response to a clinical intervention is roughly proportional to how far the patient has drifted from baseline. TRT mortality benefit concentrates in metabolically compromised men (Saad 2024 Andrology registry, HR 0.23 in highest-risk men); GLP-1 MACE reduction is biggest in the obese with established CVD (SELECT 20% MACE); MHT cardiometabolic and mortality benefits concentrate in women initiating therapy within 10 years of menopause. Healthy adults seeking optimization see much smaller absolute benefits, sometimes none.
• TRAVERSE (NEJM 2023, n=5,204) settled the decades-old testosterone–cardiovascular fear: noninferior MACE (7.0% vs 7.3%) plus a 22.5% reduction in T2D progression. FDA removed the boxed cardiovascular warning in 2025.
• SELECT (NEJM 2023, n=17,600 non-diabetic adults with overweight/obesity and CVD) showed semaglutide 2.4 mg cuts major cardiovascular events by 20% — the first weight-loss drug to deliver a hard CV outcome.
• The MHT timing hypothesis has been validated prospectively by KEEPS and ELITE: estrogen initiated within 10 years of menopause preserves endothelial function and is associated with ~30–50% lower CHD incidence and roughly RR 0.70 all-cause mortality reduction. Initiated >10 years out, the cardiovascular signal flips. Route (transdermal > oral for thrombotic safety) and progestogen choice (micronized progesterone > MPA / norethisterone for breast safety) are independently decisive. See MHT.
• First-line is lifestyle correction. Both AUA and joint endocrine guidance require optimizing sleep, OSA, exercise, alcohol, and endocrine-disrupting-chemical exposure before any hormone prescription. About 25% of men start TRT without baseline workup — skipping the easiest reversible causes.

Moderate:

• Validated epigenetic-clock deceleration is now a real pharmacological endpoint. A 32-week semaglutide RCT in HIV-lipohypertrophy moved GrimAgeV2 by −2.26 years, OMICmAge by −2.20 years, RetroAge by −2.20 years — the first drug class to do so. Population, dose, and timeframe are all narrow; the signal is real and not yet generalizable.
• The MR paradox. A 2026 Mendelian randomization (UKB n=425,097) found genetic predisposition to higher lifelong testosterone increases CAD risk in men (OR 1.17), mediated by blood pressure. Compatible with TRAVERSE because MR captures cumulative lifelong exposure, not late-life restoration — but it argues against "optimization" toward 25-year-old levels in healthy adults.

Weak / preliminary:

• Microdosing GLP-1 for longevity in healthy adults. Mechanistically plausible (most systemic geroprotective effects may occur at sub-weight-loss doses); zero RCT evidence; compounded supply chain bypasses FDA oversight. Speculative.
• Cognition and mood signals on TRT. A 2025 meta-analysis of 14 RCTs reports SMD 0.49 for executive function and 0.46 for memory in hypogonadal men. AUA still rates the cognitive benefit "inconclusive" (Grade B) — institutional lag behind the meta-analytic data.

Caution:

• TRT secondary signals from TRAVERSE. Atrial fibrillation, acute kidney injury, pulmonary embolism, and modestly elevated blood pressure on ambulatory monitoring. Erythrocytosis (hematocrit >54%) is the single most consistent adverse effect across formulations.
• GLP-1 muscle and bone losses. 25–40% of weight lost is fat-free mass; hip BMD drops ~2.6% at 52 weeks. Without 1.6–2.2 g/kg protein and 2–4 weekly resistance sessions, the drug is a path to sarcopenic obesity, not longevity.
• Compounded prescription medications. Whether semaglutide microdosing or fractionated female testosterone — both bypass FDA oversight on dose accuracy, sterility, and salt formulation. Global consensus discourages compounded female testosterone.

Practical guidance

1. Correct the reversible inputs first. Sleep, untreated OSA, alcohol, chronic stress, endocrine-disrupting chemicals, and overtraining suppress endogenous testosterone; obesity, sedentary living, and ultra-processed diet drive the metabolic dysfunction GLP-1s rescue. The clinic visit is more useful after these are addressed.
2. Get the baseline workup. Two morning testosterone draws (not one); lipid panel including apoB; HbA1c plus fasting insulin; 25-OH vitamin D; ferritin; TSH; B12 if at risk; PSA over age 40. ~25% of men start TRT without this — the most common avoidable mistake in the pillar.
3. Target the middle of the range, not the top. The MR signal on lifelong testosterone, the J-curve on most other hormones, and the Wilder pattern all argue for repletion, not optimization.
4. Scaffold prescription pharmacology with lifestyle, always. GLP-1 without resistance training and 1.6–2.2 g/kg protein is sarcopenic obesity in slow motion. TRT without OSA screening misses the cause. Statins without dietary pattern correction underdeliver.
5. Take the side effects seriously. Hematocrit >54% on TRT, BMD drops on GLP-1, atrial fibrillation signals, and the rare-but-real pancreatitis / gallbladder signal on incretins all warrant active monitoring, not assurance-by-default.
6. Hard contraindications. Pregnancy, MEN2/MTC family history, severe pancreatitis, and active eating disorders rule out GLP-1s. Active prostate cancer is no longer an absolute TRT contraindication post-TRAVERSE, but specialist co-management is the standard. Sex-hormone therapy in adults with breast or hormone-sensitive cancer history needs oncology input.

What's coming

This pillar is new (May 2026) and launches with three articles. Several adjacent topics live as cross-references in other pillars today and will be developed into dedicated L3 articles as research is provided:

• Cancer screening cadence in midlife — colorectal (USPSTF 2021 lowered to 45; NordICC 2022 deflated absolute benefit), breast (USPSTF 2024 biennial 40+), cervical (HPV primary 5-yr), prostate (the PSA shared-decision frame), lung (low-dose CT for ever-smokers), skin, AAA. Plus the overdiagnosis frame.
• Midlife labs — the cadence that's actually evidence-based — apoB / Lp(a) one-time; HbA1c + fasting insulin; ferritin (especially premenopausal women); 25-OH D; B12 in subgroups; what NOT to test (NMR LipoProfile if apoB is available, "adrenal stress" panels, food-sensitivity IgG, comprehensive heavy-metal panels in absence of exposure).
• Lipid management (apoB-first) — the modern preventive-cardiology metric; statin decision frameworks; ezetimibe; PCSK9; bempedoic acid; Lp(a)-specific therapies on the horizon.
• Blood pressure management — SPRINT/SPRINT-MIND target <130; home BP monitoring protocol; salt-sensitivity phenotyping; chronotherapy.
• Thyroid management — the TSH reference-range debate; subclinical hypothyroidism (TRUST null); Hashimoto's; T4 vs T4+T3 evidence base; the thyroid cancer overdiagnosis epidemic.
• CAC scoring and advanced cardiometabolic testing — MESA, the "warranty period" of CAC 0, CAC for statin decision in borderline cases, CCTA emerging role.
• Cortisol axis (incl. MACS) — Mild Autonomous Cortisol Secretion in adrenal incidentalomas; HPA axis diagnostics; the "adrenal fatigue" debunk vs the real cortisol-flexibility story.
• CGM in healthy adults — Stelo/Lingo OTC era; the spike-anxiety failure mode; thin evidence base for chronic non-diabetic use.

What this category is not

• Not medical advice. The doses, thresholds, and interventions discussed are evidence summaries, not prescribing recommendations. Decisions on a specific patient belong to a specific clinician.
• Not a "preventive optimization" pillar. The site's hierarchy is lifestyle first; this pillar exists because some interventions only happen through a clinician (prescriptions, screening tests, controlled labs), not because pills outperform behavior.
• Not a marketing surface. No brand promotion; the article titles use household names (Ozempic-class drugs) for plain language, not endorsement.

---